CMND

Business Context and Reporting Period

Company: Clearmind Medicine Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 19, 2025
Reporting Period: Month of November 2025
Context: The Company announced a registered direct offering of common shares to raise capital for general corporate purposes, including research and development.

Key Financial Metrics

Offering Details:

• Shares Issued: 10,925,000 Common Shares
• Purchase Price: $0.20 per share
• Expected Gross Proceeds: Approximately $2.185 million
• Expected Closing Date: On or about November 20, 2025

Use of Proceeds: Operating expenses, research and development (clinical and pre-clinical testing), working capital, future acquisitions, and general capital expenditures.
Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity positions.

Material Changes

This filing reports a material capital event rather than a change in operating performance metrics. The primary change is the execution of a Securities Purchase Agreement for the sale of equity, which will increase the Company's share count and cash reserves upon closing. No comparative financial data for prior periods is included in this document.

Guidance, Outlook, and Risks

Outlook: Management intends to utilize the net proceeds to advance product candidates and fund general corporate needs.
Risks and Contingencies:

• Closing Conditions: The Offering is subject to customary closing conditions; failure to satisfy these may prevent the transaction from closing.
• Forward-Looking Statements: The filing contains forward-looking statements regarding the closing date and use of proceeds, which are not guaranteed and are subject to risks beyond the Company's control.
• Legal Restrictions: The report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration.

Unusual Items: None reported beyond the standard terms of the registered direct offering.

Investor Verification Checklist

• Confirm the actual closing of the Offering on or about November 20, 2025.
• Verify the final number of shares issued and the exact gross proceeds received.
• Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
• Monitor subsequent filings for updates on the allocation of proceeds to specific R&D milestones.